Foley Hoag is proud to sponsor LSX World Congress USA 2025, a premier gathering of leaders from the US biotech, medtech, and pharmatech sectors. This event provides a unique platform for CEOs, investors, and pharma executives to network, showcase innovations, and explore partnership opportunities, all while shaping the future of healthcare technology through meaningful discussions and collaborative sessions.
Partner and Life Sciences Industry Group Co-Chair Jeff Quillen will speak at the keynote session, “Investing in Biotech Breakthroughs: A VC Outlook” on September 16th at 11 AM ET. This panel of leading investors will explore the 2025 funding landscape so far and the outlook for the remainder of the year, diving into the forces shaping the industry and the cutting-edge therapies of tomorrow. This candid discussion will examine where capital is flowing, how companies are adapting, and what the future holds for biotech breakthroughs. Key topics include:
- Overview of the key biotech investment trends so far in 2025
- What are the most critical factors—economic, regulatory, technological—that will impact biotech over the next 12-24 months and beyond? How can companies prepare for these shifts?
- How are investors balancing investments in early-stage versus late-stage biotech companies?
Partners Susan Abelleira, Brendan Burke, Kevin Lin, Ariana Harris, and John Harre will participate in the LSX World Congress Strategic Partnering Forum with one-on-one meetings that bring together innovative biotech companies and senior executives from leading pharmaceutical organizations in an intimate setting designed to foster meaningful collaborations.
